Preventing Respiratory Injury From Indoor Biomass Exposure

Abstract

Indoor biomass exposure is a globally pervasive risk factor for respiratory morbidity and mortality, particularly in low- and middle-income countries. The combustion of biomass fuels—such as wood, crop residues, and animal dung—produces a complex mixture of particulate matter and toxic gases, significantly elevating the risk of acute and chronic respiratory diseases. This review synthesizes current epidemiological, mechanistic, and clinical evidence on the respiratory effects of indoor biomass exposure, highlights key risk factors and clinical presentations, and examines both established and emerging strategies for prevention and management. Attention is given to recent advances, guideline-based recommendations, and the practical implications for healthcare professionals striving to reduce disease burden and improve patient outcomes.

Introduction

The use of biomass fuels for cooking and heating remains prevalent worldwide, exposing nearly three billion people to hazardous indoor air pollution. Biomass combustion generates fine particulate matter (PM2.5), carbon monoxide, nitrogen oxides, volatile organic compounds, and polycyclic aromatic hydrocarbons—each implicated in respiratory tract injury. Health professionals increasingly encounter patients affected by the sequelae of chronic exposure, necessitating a thorough understanding of the epidemiology, pathophysiology, clinical patterns, and evidence-based preventive interventions for respiratory injury resulting from indoor biomass exposure.

Epidemiology / Disease Burden

Globally, indoor air pollution from biomass fuels accounts for more than four million premature deaths annually, with a disproportionate burden in sub-Saharan Africa, South Asia, and Latin America. Women and young children, who spend extensive time near household stoves, are especially vulnerable. Epidemiological studies have demonstrated a strong association between biomass smoke exposure and increased incidence of acute lower respiratory infections (ALRI) in children, chronic obstructive pulmonary disease (COPD), asthma exacerbations, and, to a lesser extent, lung cancer. The World Health Organization (WHO) identifies indoor air pollution as a leading modifiable environmental health risk, underscoring its significance for clinical practice and public health policy.

Pathophysiology

Biomass combustion releases a heterogeneous mix of inhalable particles and gases. Fine PM2.5 penetrates deep into the alveolar spaces, inciting oxidative stress, inflammation, and epithelial injury. Chronic exposure impairs mucociliary clearance, disrupts epithelial barrier function, and promotes airway remodeling. Carbon monoxide competitively inhibits oxygen binding to hemoglobin, exacerbating tissue hypoxia. Repeated exposure can trigger both innate and adaptive immune responses, leading to persistent airway inflammation, fibrosis, and increased susceptibility to infections. The pathophysiological cascade explains the spectrum of acute and chronic respiratory diseases observed in exposed populations.

Risk Factors

Key risk factors for respiratory injury from indoor biomass exposure include type of biomass fuel (wood, dung, crop residues), inefficient stoves, poor household ventilation, duration and intensity of exposure, and host factors such as age, pre-existing cardiorespiratory disease, nutritional status, and genetic susceptibility. Socioeconomic determinants—such as poverty, limited access to cleaner fuels, and educational disparities—further compound the risk, necessitating context-specific preventive strategies.

Clinical Features

Patients exposed to indoor biomass smoke may present with a range of clinical manifestations. Acute symptoms include cough, wheezing, dyspnea, and exacerbation of underlying respiratory conditions. In children, exposure substantially increases the risk of ALRI, including pneumonia and bronchiolitis. Chronic exposure is associated with the development and progression of COPD, characterized by chronic cough, sputum production, and airflow limitation. Asthma and interstitial lung diseases have also been linked to biomass exposure. In severe cases, hypoxemia and respiratory failure may occur, especially in vulnerable populations.

Diagnosis

Diagnosis relies on a high index of suspicion based on clinical presentation and a detailed exposure history, including type of fuel, duration of exposure, and household ventilation characteristics. Pulmonary function testing often reveals obstructive or mixed ventilatory defects in chronic cases. Imaging may demonstrate hyperinflation, bronchial wall thickening, or interstitial changes. Biomarkers of inflammation and oxidative stress are under investigation but not yet standard in clinical practice. Differentiating biomass-related respiratory disease from tobacco-related or occupational exposures remains challenging and requires careful clinical assessment.

Treatment & Management

Management is multifaceted, encompassing both symptomatic treatment and exposure reduction. Acute respiratory symptoms are managed according to standard protocols for infections, asthma, or COPD exacerbations. Long-term management focuses on optimizing respiratory function, preventing complications, and minimizing further exposure. Inhaled bronchodilators, corticosteroids, and pulmonary rehabilitation may be beneficial for chronic airway disease. Critically, effective management mandates a strong emphasis on exposure reduction through patient education, household modifications, and advocacy for cleaner fuels and improved stove technologies.

Recent Advances / Emerging Therapies

Recent innovations include the development and dissemination of advanced cookstoves with improved combustion efficiency and lower emissions. Community-based interventions promoting cleaner fuels such as liquefied petroleum gas (LPG) and biogas have demonstrated reductions in household PM2.5 levels and improvements in respiratory outcomes. Emerging research focuses on the use of antioxidants and anti-inflammatory pharmacotherapies to mitigate the effects of chronic exposure, although robust clinical trial data are pending. Mobile health (mHealth) interventions are being piloted to enhance patient education and monitoring in resource-limited settings.

Guideline Recommendations

Current international guidelines, including those from the WHO and Global Initiative for Chronic Obstructive Lung Disease (GOLD), emphasize the primary importance of exposure reduction as the cornerstone of prevention. Recommendations include transitioning to cleaner fuels, improving household ventilation, and adopting modern stove technologies. Healthcare professionals are advised to incorporate exposure assessment into routine clinical evaluations, counsel patients on risk mitigation, and collaborate with public health agencies to address social determinants of health. Vaccination against influenza and pneumococcus is recommended for high-risk individuals to reduce the burden of secondary infections.

Conclusion

Respiratory injury from indoor biomass exposure is a preventable yet pervasive contributor to global respiratory disease burden. Clinicians play a pivotal role in early recognition, risk stratification, and management of affected patients. Advances in clean stove technology, fuel transitions, and public health interventions offer promising avenues for primary prevention. Continued research into pathophysiological mechanisms, targeted therapies, and implementation science will further inform evidence-based strategies to protect vulnerable populations and reduce morbidity and mortality associated with indoor biomass exposure.